The Rapid Case Ascertainment program (RCA) was developed in 1986-1987 to facilitate populationbased studies of cancer that propose to use the State of Connecticut as a population laboratory. It was incorporated as a YCC Shared Resource on January 1, 1995, and approved by the NCI for July 1, 1998. RCA functions as a field arm of the Connecticut Tumor Registry, the oldest population-based cancer registry in the country, and since 1973 an NCI-SEER site. RCA addresses the many requirements and administrative tasks common to all proposed hospital-based research in the state, and provides uniformly high-quality interface with those individuals, institutions and agencies who are crucial to the success of population-based cancer prevention and control research. Initiation of hospital-based research in Connecticut is complicated. Individual hospital requirements and personnel are always changing. Prior to RCA, an investigator who had a single study, a definitive funding period, and perhaps limited knowledge of inter-institutional policies, personalities, and politics had to spend an inordinate amount of time on nonscientific related effort to obtain and maintain the necessary approvals to conduct the research. Major services provided to investigators are: consulting and assisting in protocol writing in appropriate areas (protection of human subjects/ HIPAA, confidentiality, design of required institution-specific consent documents, etc.);obtaining all non-Yale approvals to conduct the research (State of CT, all community hospital IRBs, hospital administrative and departmental approvals, where necessary);providing names of patients with incident cancers by surveying all hospitals;and submitting annual reports and requests for re-approvals to all non-Yale IRBs. RCA services geared to enhance and strengthen the partnership of investigators and data sources are: providing feed-back of all published results of research to participating institutions;recognizing and acknowledging in print those institutions which participate in the research;and acting as a resource to the health care community in those areas relating to cancer prevention and control, including facilitating interaction between investigators with common interests and goals. RCA is a critical part of the YCC Program in Cancer Prevention and Control Research, as well as the Cancer Genetics Program. In 2005, 90% of RCA's overall use was by YCC members (52% peerreviewed YCC Members) from the Cancer Prevention &Control and the Cancer Genetics Research Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916703
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$65,610
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications